PMCB earnings analysis
What we found in PMCB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
PharmaCyte Biotech, in its Q3 2026 10-Q filing, reported no revenue for the quarter, with a diluted EPS loss narrowing to -$0.17 versus prior quarters. The company has faced increasing general and administrative expenses and continued to incur significant losses in other income due to fair value adjustments. Management underscored ongoing challenges related to FDA approvals and a cautious approach to capital investments amid cash reserves totaling approximately $20.2 million.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- No Revenue Generation
- PharmaCyte generated $0 in revenue for Q3 2026, consistent with the previous year.
- Reduced R&D Expenses
- R&D expenses decreased by 21% from $118,196 in Q3 2025 to $93,113 in Q3 2026.
- Surge in G&A Expenses
- G&A expenses soared 141% year-over-year from $842,056 to $2,024,989 due to increased stock-based compensation and consulting fees.
- Positive Cash Position
- The company reported an increase in cash and equivalents to approximately $20.2 million as of January 31, 2026, up from $15.2 million at April 30, 2025.
- Successful Stabilization Studies
- Completed required stability studies for product candidates, addressing critical FDA requests.
- Clarity on Cash Utilization
- Net cash used in operating activities totaled $3,760,352 primarily linked to administrative costs and legal settlements.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq Compliance Concerns
- Non-compliance with Nasdaq's minimum bid price requirement could result in delisting by June 1, 2026.
- Inordinate Clinical Hold Delays
- Extended delays in lifting the FDA's clinical hold on IND submissions may affect product development timelines.
- Increased Capital Requirements
- Potential future capital raises may lead to significant shareholder dilution, affecting ownership stakes.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.17
What they said about what is next.
No explicit revenue or EPS guidance provided; financial viability projected through existing cash reserves.
The filing reads worse than the one before it.
What came before.
- 10-Q · December 18, 2025
- PharmaCyte Biotech, Inc. reported no revenues for Q2 FY2026, with a diluted EPS of -1.24, reflecting a significant decline in financial performance. Notably, R&D expenses increased to $141,085 from $97,470…
- 10-Q · September 15, 2025
- PharmaCyte Biotech, Inc. reported no revenue for the three months ending July 31, 2025, consistent with the prior year. Research and development expenses decreased slightly to $95,157, while general and administrative…
- 10-K · August 11, 2025
- PharmaCyte Biotech, Inc. reported no revenue for the fiscal year ending April 30, 2025, but showed a significant increase in net income due to gains from investments in preferred stocks and changes in fair market value…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PMCB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever